Local Anesthetics Flashcards

1
Q

What are local anesthetics?

A
  • drugs that reversibly block conduction of electrical impulses along nerve fibers
  • MAJOR component of clinical anesthesia and is increasing used to treat chronic and acute pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How many nodes of ranvier in a myelinated axon does a local anesthetic need to inhibit to block impulses?

A

3 successive nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

fasciculi

A
  • bundles of axons
  • covered with three layers of connective tissue
  • LAs must diffuse through these to exert their effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

endoneurium

A
  • thin, delicate collagen that embeds the axon in the fascicule
  • around each little fascicle
  • don’t want to inject LA here because can increase the pressure and compress causing a nerve injury
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

perineurium

A
  • consists of layers of flattened cells that binds groups of fascicles together
  • covers nerve root
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

epineurium

A
  • surrounds the perineurium and is composed of connective tissue that holds fascicles together to form a peripheral nerve
  • surrounds nerve bundle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

RMP of axon

A

-70 to -90 mV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

LA MOA

A
  • bind to specific sites on Na+ channel
  • block transmission of nerve impulses
  • LA do not alter the RMP or threshold potential
  • diffusion of unionized based across the nerve sheath and membrane
  • re-equilibrium between the base and cationic forms in the axoplasm
  • binding of the cation to a receptor inside the sodium channel inside the cell resulting in its blockade and inhibition of Na+ conduction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

LA specific binding sites

A
  • preferential binding to OPEN and INACTIVE Na+ channel states
  • also blocks K+ channels, Ca2+ channels, and GPCRs to a lesser extent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

frequency dependent blockade

A
  • resting nerve is less sensitive to LA than one repeatedly stimulated –> AKA use dependent or phasic block
  • quicker block potentially if person is actively using nerve
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

differential blockade

A
  • nerves have different sensitivity when exposed to LA
  • smaller diameter and lack of myelin enhance sensitivity
  • larger nerves conduct impulses faster and are harder to block
  • in general it goes preganglionic –> loss of sensation –> loss of motor movement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

type A alpha

A
  • function is proprioception, motor
  • diameter is 6-22 um
  • heavy myelination
  • last/longest to block onset
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

type A beta

A
  • function is touch, pressure
  • diameter is 6-22 um
  • heavy myelination
  • block onset intermediate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

type A gamma

A
  • function is muscle tone
  • diameter is 3-6 um
  • heavy myelination
  • block onset intermediate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

type A delta

A
  • function is pain, cold temperature, touch
  • diameter 1-5 um
  • heavy myelination
  • block onset intermediate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

type B

A
  • function preganglionic autonomic vasomotor
  • diameter < 3um
  • light myelination
  • block onset early
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

type C sympathetic

A
  • function is postganglionic vasomotor
  • diameter 0.3-1.3 um
  • no myelination
  • block onset early
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

type C dorsal root

A
  • function pain, warm and cold temperature, touch
  • diameter 0.4-1.2 um
  • no myelination
  • block onset early
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

three characteristic segments of LAs

A
  • unsaturated aromatic (benzene) ring system (the lipophilic portion)
  • tertiary amine (hydrophilic portion)
  • either an ester or an amide linkage binds the aromatic ring to the carbon group
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ester local anesthetics

A
  • procaine
  • chloroprocaine
  • tetracaine
  • cocaine
  • benzocaine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

amide local anesthetics

A
  • lidocaine
  • mepivacaine
  • prilocaine
  • bupivacaine
  • ropivacaine
  • articaine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

why is the ester or amide linkage important

A
  • clinically relevant because of its implications for metabolism, duration, and allergic potential
  • changes in chemical structure affect drug potency, speed of onset, duration of action, and differential block potential
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

differences between ester and amide LAs

A
  • ester catalyzed by plasma and tissue cholinesterases by hydrolysis while amides metabolized in liver by CYP1A2 and CYP3A4
  • esters have a higher potential for allergy (bc breakdown into PABA) while allergy to amides is very rare
  • ester drugs tend to be shorter acting due to ready metabolism; amides are longer acting because they are more lipophilic and protein bound
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

minimum effective concentration (Cm)

A
  • minimum concentration of LA necessary to produce conduction blockade of a nerve impulse (analogous with MAC)
  • Cm of motor approximately twice that of sensory fibers
  • less LA needed for intrathecal vs epidural
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

PK/PD of LA

A
  • agents meant to remain localized in area of injection
  • higher the concentration injection, the faster the onset
  • systemic absorption –> termination of drug
  • absorption also influences drug termination and toxicity
  • the slower the LA is absorbed, the less likely toxicity
  • metabolism and elimination readily keep up
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Potency of LA

A

strong relationship between potency and lipid solubility; larger lipid-soluble LA are water insoluble and highly protein bound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

what does lipid solubility of LA correlate with?

A
  • protein binding
  • increased potency
  • longer DOA
  • tendency for severe cardiac toxicity
  • amides usually more lipid soluble/protein bound than esters
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

LA DOA

A
  • relationship between protein binding and lipid solubility; drug tends to remain in vicinity of Na+ channel
  • LA = weak bases and bind to alpha1 acid glycoprotein (also albumin but to a lesser extent)
  • injection site also plays a major role in DOA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

LA onset of action

A
  • how readily LA diffuses across axolemma (axon cell membrane) depends on chemical structure
  • LA = weak bases
  • basic drugs become MORE ionized when placed in a solution with a pH < pKa
  • drugs with a pKa closer to physiologic pH have a faster onset
  • **EXCEPTION = chloroprocaine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Tetracaine pKa

A

8.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Tetracaine % ionized at pH 7.4

A

93%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

tetracaine % protein bound

A

94%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

tetracaine onset

A

slow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

tetracaine DOA

A

180-600 min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

lidocaine pKa

A

7.9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

lidocaine % ionized at pH 7.4

A

76%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

lidocaine % protein bound

A

64%; more available free drug so shorter DOA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

lidocaine onset

A

fast

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

lidocaine DOA

A

90-120 min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

bupivacaine pKa

A

8.1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

bupivacaine % ionized at pH 7.4

A

83%

42
Q

bupivacaine % protein bound

A

95%; less free drug available; longer DOA

43
Q

bupivacaine onset

A

slow

44
Q

bupivacaine DOA

A

180-600 min

45
Q

LAs vasomotor action

A
  • LA cause relaxation of smooth muscle (lidocaine, ropivacaine, and cocaine are the exceptions)
  • relaxation –> vasodilation that decreases DOA, increases plasma concentration, potential toxicity
46
Q

LA absorption

A
  • speed of absorption has toxicity implications

- total dose of LA determines plasma level, not volume or concentration

47
Q

LA route of administration highest to lowest blood concentration

A
  • IV
  • tracheal
  • caudal
  • paracervical
  • epidural
  • brachial
  • sciatic
  • subcutaneous
48
Q

common additives in LA

A
  • epinephrine
  • sodium bicarbonate
  • clonidine
  • dexmedetomidine
  • opioids
  • ketorolac
  • dexamethasone
  • hyaluronidase
49
Q

epinephrine in LAs

A
  • vasoconstrictor that reduces rate of vascular absorption of LAs
  • leads to increased duration/potency of block
  • decreases risk of systemic toxicity
  • does not have equal effects for all LAs
  • lidocaine, mepivacaine, and procaine (greater effect with local infiltration, peripheral block, and epidural)
  • prilocaine and bupivacaine (lesser effect; prolonged with peripheral nerve block but not epidural)
50
Q

sodium bicarbonate in LAs

A
  • common in epidural anesthesia
  • adding bicarb raises pH of LA solution resulting in more drug in nonionized state
  • may result in less pain on injection
  • major limitation = precipitation
51
Q

LA distribution

A
  • absorption or injection of LA into systemic circulation –> rapid redistribution
  • distribution of esters and amides are similar
  • decrease in plasma concentration to highly perfused tissue (brain, heart, lungs receive most initially; can be a concern due to toxicity)
  • secondary distribution to rest of body - muscle receives most
52
Q

ester LA metabolism

A
  • plasma esterases catalyze their hydrolysis
  • procaine and chloroprocaine have plasma half life less than 1 min
  • atypical plasma cholinesterase can increase risk of toxicity
53
Q

amide LA metabolism

A
  • metabolism of amide LA occurs in liver via CYP450 enzyme

- severe hepatic disease can prolong metabolism

54
Q

LA excretion

A
  • renal dysfunction affects clearance far less than hepatic failure
  • hepatic failure – affect protein binding to both AAG and albumin
55
Q

Pregnancy LA considerations

A
  • mechanical changes in pregnancy - reduction in epidural space; you could cause compression of the space if you give to much and then cause movement of LA up and down epidural space
  • hormonal changes - progesterone levels may affect sensitivity to LA
56
Q

LAST

A
  • local anesthetic systemic toxicity
  • serious but rare event during regional anesthesia
  • most commonly occurs with inadvertent IV injection
  • shorter acting drugs thought to be less cardiotoxic (esters, bc metabolized much quicker)
57
Q

MOA of LAST

A
  • IV injection of LA
  • initial blocking of inhibitory neurons thought to cause seizures
  • blocking of cardiac ion channels results in bradycardia
  • ventricular fibrillation = most serious complication
58
Q

LAST clinical presentation

A
  • rapid onset usually within a minute
  • FIRST - agitation, tinnitus, circumoral numbness, blurred vision, metallic taste
  • THEN - muscle twitching, unconsciousness, seizures
  • VERY high levels - cardiac and respiratory arrest
59
Q

LAST incidence

A

0.4 per 10,000 cases

60
Q

LAST most common in

A
  • epidural
  • axillary
  • interscalene
61
Q

prevention strategies for LAST

A
  • test dose
  • incremental injection with aspiration
  • use of pharmacologic markers
  • ultrasound
62
Q

LAST treatment

A
  • prompt recognition and diagnosis!!
  • airway management = priority
  • seizure suppression - benzos, succs
  • prevent hypoxia and acidosis
  • lipid emulsion therapy
  • vasopressors - EPI; NO vasopressin
  • ACLS/cardiopulmonary bypass/ECMO if severe
63
Q

LAST lipid emulsion therapy MOA

A
  • capture LA in blood - lipid sink
  • increase fatty acid uptake by mitochondria
  • interference of Na+ channel binding
  • promotion of calcium entry
  • accelerated shunting
64
Q

lidocaine max doses

A
  • 4 mg/kg

- 7 mg/kg with epi

65
Q

mepivacaine max doses

A
  • 4 mg/kg

- 7mg/kg with epi

66
Q

bupivacaine max dose

A

-3 mg/kg

67
Q

ropivacaine max dose

A

-3 mg/kg

68
Q

tetracaine max dose

A

-3 mg/kg

69
Q

LA SE/considerations

A
  • allergic reactions
  • methemoglobinemia
  • cauda equina syndrome (CES)
  • transient neurologic syndrome (TNS)
70
Q

LA allergic reactions

A
  • more common in ester LA
  • esters metabolized to derivatives of para aminobenzoic acid (PABA)
  • cross reactivity to other esters but not amides
  • amide related allergies more commonly associate with preservatives
71
Q

methemoglobinemia

A
  • high concentration of methemoglobin in the blood
  • ferris form of hemoglobin (Fe2+) converted to ferric hemoglobin (Fe3+)
  • presents as decreasing oxygen saturation not responsive to therapy
  • benzocaine-induced methemoglobinemia (rise in cases since 2006; many involve infants less than 2 yo)
  • prilocaine can cause also because metabolite is o-toluidine; dose should not exceed 2.5 mg/kg; avoid in children, pregnant women, pt taking oxidizing drugs
  • treatment methylene blue 1-2 mg/kg over 3-10 min
  • high level of methemoglobinemia may require transfusion or dialysis
72
Q

cauda equina syndrome (CES)

A
  • manifests as bowel and bladder dysfunction with lower extremity weakness and sensory impairment related to cord ischemia
  • risk factors - supernormal doses of LA
  • maldistribution of LA within intrathecal space
73
Q

transient neurologic symptoms (TNS)

A
  • associated with intrathecal lidocaine
  • presentation - burning, aching, cramp like pain in low back and radiating down thighs for up to 5 days post-op
  • risk factors - lithotomy and outpatient surgery
74
Q

Lidocaine facts

A
  • discovered in 1943 by Nils Löfgren in Sweden
  • on WHO list of essential meds
  • weak base
75
Q

Lidocaine PK/PD

A
  • pKa slightly above physiologic pH (7.9)
  • protein binding 70-90%
  • DOA 90-120 min
  • max dose 4 mg/kg or 7 mg/kg with epi
76
Q

what lidocaine concentration would you use for labor epidural test dose?

A

lidocaine 1.5% with epi 1:200,000

77
Q

clinical uses for lidocaine

A
  • antiarrhythmic
  • topical
  • induction (blunt SNS)
  • nebulized
  • multimodal pain management
  • regional anesthesia
78
Q

ACLS algorithm and lidocaine

A
  • depresses myocardial automaticity

- class 1B anitarrhythmic

79
Q

ACLS VT/VF lidocaine dose

A

1-1.5 mg/kg IV or IO
0.5-0.75 mg/kg (refractory)
3 mg/kg (total)
maintenance infusion 1-4 mg/min (30-50 mcg/kg/min)

80
Q

Topical lidocaine

A
  • EMLA = eutetic mixture of local anesthetics; 1:1 lidocaine prilocaine mixture
  • contraindications - mucous membranes, broken skin, infants <1 month, history of methemoglobinemia
81
Q

lidocaine for induction

A
  • 1-1.5 mg/kg, 1-3 min prior to laryngoscopy
  • to decrease pain of propofol
  • attenuate CV response to intubation
  • attenuate increase in ICP in patients with decreased compliance
  • study shows 2 mg/kg completely attenuates cough given 1-5 min prior to intubation
82
Q

pain of propofol and lidocaine

A
  • pain = phenol
  • 1 mL of 2% lidocaine reduced pain on injection from 70% to 30%
  • most significant interventions to reduce pain –> AC vein, veno occlusion, small dose of opioids
  • 20 mg lidocaine in 10 mL with venous occlusion for 60 seconds
83
Q

topical lidocaine

A

-decreasing emergence phenomenon - coughing, sore throat, dysphonia

84
Q

LTA

A
  • laryngotracheal topical anesthesia
  • administered at induction has little effect o prevention of coughing during extubation; best to admin closer to the time of extubation; admin 30 prior to extubation = significant decrease
85
Q

best way to prevent emergence phenomenon

A
  • ETT alkalized lidocaine, shown to prevent EP more than any other technique
  • approximately 60 min required to achieve desired effect
  • adding bicarb increases non-ionized fraction of drug
  • low dose alkalized lidocaine (40 mg) shown more effective
86
Q

ETT alkalized lidocaine technique

A
  • should use a manometer each time they fill the ETT
  • achieve correct pressure using air first
  • remove and record amount of air required
  • add 2 mL lidocaine
  • add 1-2 mL of bicarb
  • add saline to match cuff volume
  • need at least 60 min for lidocaine to diffuse/leak out of cuff
87
Q

airway block

A
  • nebulized lidocaine

- 4% lidocaine applied directly to oropharynx

88
Q

transtracheal block

A

-4% lidocaine injected through the cricothyroid membrane

89
Q

lidocaine in multimodal pain management

A
  • often part of ERAS protocols
  • used to supplement general anesthesia
  • 1.5 mg/kg bolus dose
  • 2 mg/kg/hr infusion
  • goal = give a lot less narcotic
90
Q

lidocaine inufsion

A
  • MOA of IV lidocaine relatively unknown - may involve sodium channels, block priming of polymorphonuclear granulocytes
  • not beneficial for all surgeries
  • shown to reduce post-op pain and speed up return of bowel function in open and laparoscopic procedures
  • decreases pain and improves functional outcomes in prostatectomy, thoracic, and spine cases
  • accumulation = concern, but ERAS usually way under toxicity
  • monitor patients at risk
91
Q

bier block

A
  • IV regional anesthesia
  • short procedures
  • 25-50 mL of 0.5% lidocaine
  • onset time 5-10 min
  • tourniquet pain at 20 min
92
Q

lidocaine plasma concentration 1-5 mcg/mL

A

analgesia

93
Q

lidocaine plasma concentration 5-10 mcg/mL

A
  • circumoral numbness
  • tinnitis
  • skeletal muscle twitching
  • systemic hypotension
  • myocardial depression
94
Q

lidocaine plasma concentration 10-15 mcg/mL

A
  • seizure

- unconsciousness

95
Q

lidocaine plasma concentration 15-25 mcg/mL

A
  • apnea

- coma

96
Q

lidocaine plasma concentration >25 mcg/mL

A

cardiovascular collapse

97
Q

Exparel

A
  • new generation LA
  • injected directly into surgical site
  • shown to provide reduced opioid requirements for up to 72 hours (up to 28% reduction in opioids)
  • bupivacaine + liposomal agent DepoFoam
  • multivesicular liposomes composed of honeycomb-like structure of numerous aqueous chambers
  • lipid membrane separate each chamber
  • each chamber encapsulates bupivacaine
  • dose based on surgical site and volume required to cover area
  • part of multimodal treatment regimen to provide non-opioid pain control
98
Q

liposomal LAs administration

A
  • single-dose infiltration only
  • admin with a 25G or larger bore needle
  • not to exceed 266 mg (20mL 1.3% of undiluted drug)
  • inject slowly via infiltration into surgical site with frequent aspiration to minimize the risk of IV injection
  • do not administer product if discolored
99
Q

liposomal LAs anesthetic considerations

A
  • do not mix with non-bupivacaine LAs

- use cautiously in patients with hepatic disease

100
Q

liposomal LAs contraindications

A

OB paracervical block

101
Q

Exparel NOT used for

A
  • patients < 18 years
  • epidural or intrathecal anesthesia
  • peripheral nerve block
102
Q

liposomal LAs adverse effects

A
  • > 10% N/V

- <10% dizziness, tachycardia, HA, somnolence, bradycardia, hypoesthesia, lethargy